CRISPR Therapeutics AG

AI-generated fair value estimate for this company.

Method: Sum-of-the-parts NPV: 10-year DCF of projected Casgevy royalty/collaboration revenue starting from $156.6M (2027E) growing 35% then decelerating to 5% by year 10, 80% royalty margin, 11% discount rate, 3% terminal growth, plus $1.58B net cash; 96.69M diluted shares outstanding.

Reasoning: CRISPR Therapeutics has near-zero self-generated product revenue today but a very strong balance sheet ($2.36B cash, minimal debt) and a ramping royalty stream from Vertex's Casgevy; value is best captured as net cash plus a risk-weighted NPV of the royalty ramp rather than a standard FCF DCF on currently volatile, near-zero revenue.